Opdivo (nivolumab) | Friends of Cancer Research

You are here

Opdivo (nivolumab)

Sponsor: 
Bristol-Myers Squibb Company
Indication: 
In combination with ipilimumab, for treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC
Category: 
Year: 
2018
Date: 
Feb 16th
FDA Status: 
FDA Approval
Approval Date: 
Apr 16th
Approval Year: 
2018